Department of Child Neurology, Medical University of Warsaw, Poland.
Department of Diagnostic Imaging, The Children's Memorial Health Institute, Warsaw, Poland.
Neurol Neurochir Pol. 2021;55(5):429-439. doi: 10.5603/PJNNS.a2021.0063. Epub 2021 Sep 20.
Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients. However, reports of adverse events of VGB, including VGB-associated visual field loss and brain abnormalities in neuroimaging, have raised concerns about the broader use of VGB and thus significantly limited its application.
The goal of this review was to summarise the recent therapeutic guidelines, the use of VGB in focal seizures and new VGB applications as a disease-modifying treatment in TSC patients. Moreover, we discuss the current opinions on potential VGB-associated toxicity and the safety of VGB.
氨己烯酸（VGB）是第二代抗癫痫药物，对婴儿痉挛症和局灶性癫痫发作有治疗作用，主要用于结节性硬化症（TSC）患者。然而，VGB 相关的不良事件报告，包括 VGB 相关的视野丧失和神经影像学中的脑异常，引起了对 VGB 更广泛使用的关注，因此大大限制了其应用。
本综述的目的是总结最近的治疗指南、VGB 在局灶性癫痫发作中的应用以及 VGB 作为 TSC 患者疾病修饰治疗的新应用。此外，我们还讨论了目前对潜在的 VGB 相关毒性和 VGB 安全性的看法。
